Inhibition of Hypoxia-Inducible Factor Is Sufficient for Growth Suppression of VHL-/- Tumors

Molecular Cancer Research

Volumn 2, Issue 2, 2004, Pages 89-95

  Zimmer, Michael ^a   Doucette, Darrell ^a   Siddiqui, Naila ^a   Iliopoulos, Othon ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEASOME; RNA; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME SUBSTRATE; GENE CONTROL; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR XENOGRAFT; UBIQUITINATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL DIVISION; CELL LINE, TUMOR; ENDOTHELIAL CELLS; GENE DELETION; HUMANS; KIDNEY NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; RNA INTERFERENCE; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

ANIMALIA; MAMMALIA; MUS MUSCULUS;

EID: 1342280515     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lisztwan J, Imbert G, Wirbelauer C, et al. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev, 1999;13:1822-33.
2. Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science, 1999;284:455-61.
3. Maher E, Kaelin WG. von Hippel-Lindau disease. Medicine, 1997;76:381-91.
4. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet, 1994;7:85-90.
5. Maxwell PH, Wiesener MS, Chang GW, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999;399:271-5.
6. Kuznetsova AV, Meller J, Schnell PO, et al. von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci, 2003;100:2706-11.
7. Na X, Duan HO, Messing EM, et al. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J, 2003;22:4249-59.
8. Iliopoulos O, Jiang C, Levy AP, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci, 1996;93:10595-9.
9. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci, 1996;93:10589-94.
10. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem, 1996;271:2746-53.
11. Iliopoulos O, Kibel A, Gray S, et al. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med, 1995;1:822-6.
12. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol, 2000;2:423-7.
13. 2-regulated prolyl hydroxylation. Science, 2001;292:468-72.
14. Ivan M, Kondo K, Yang H, et al. HIF1α targeted for VHL-mediated destruction by proline hydroxylation: implications for oxygen sensing. Science, 2001;292:464-8.
15. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev, 2001;11:293-9.
16. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci, 1999;24:68-72.
17. Harris AL. Hypoxia: a key regulatory factor in tumor growth. Nat Rev Cancer, 2002;2:38-47.
18. Seagroves TN, Ryan HE, Lu H, et al. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol, 2001;21:436-44.
19. Elson DA, Thurston G, Huang LE, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev, 2001;15:2520-32.
20. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature, 1998;394:485-90.
21. Maranchie JK, Vasselli JR, Riss J, et al. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell, 2002;1:247-55.
22. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res, 1999 Nov 15;59(22):5830-5.
23. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia inducible factors HIF1α and HIF2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol, 2000;157:411-21.
24. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst, 2001;93:309-14.
25. Ryan HE, Lo L, Johnson RS. HIF1α is required for solid tumor formation and embryonic vascularization. EMBO J, 1998;17:3005-15.
26. Kung AL, Wang S, Klco JM, et al. Suppression of tumor growth disruption of hypoxia-inducible transcription. Nat Med, 2000;6:1335-40.
27. Sowter HM, Raval R, Moore J, et al. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res, 2003;63:6130-4.
28. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell, 2002;1:237-46.
29. 2 in muscle cells in culture. Am J Physiol, 1992;262:C682-90.
30. Brusselmans K, Bono F, Maxwell P, et al. Hypoxia-induciblc factor-2α (HIF-2α) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J Biol Chem, 2001;276:39192-6.
31. Williams KJ, Telfer BA, Airley RE, et al. A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene, 2002;21:282-90.
32. Park SK, Dadak AM, Haase VH, et al. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1α (HIF-1α): role of cytoplasmic trapping of HIF-2α. Mol Cell Biol, 2003;23:4959-71.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 2000;100:57-70.
34. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol, 2002;22:7004-14.
35. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol, 2001;21:3995-4004.
36. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev, 2000;14:391-6.
37. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev, 2000;14:33-44.
38. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov, 2003;2:803-11.
39. Williams RD, Elliott AY, Stein N, et al. In vitro cultivation of human renal cell cancer. 1. Establishment of cells in culture. In Vitro, 1976;12:323-7.